No abstract is available for this article. References 1, , , et al. Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for the treatment of Takayasu arteritis. Arthritis Rheumatol 2023. doi: https://doi.org/10.1002/art.42496. Epub ahead of print. 2, , , et al. Novel Th17 lymphocyte populations, Th17.1 and PD1+Th17, are increased in Takayasu arteritis, and both Th17 and Th17.1 sub-populations associate with active disease. J Inflamm Res 2022; 15: 1521– 41. 3, , , et al.